APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Retinal Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Long-acting Retinal Drugs Market Analysis and Forecast 2026-2032

23 December 2025200 pages

Choose your research edition.

Industry ResearchLong-acting Retinal Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Retinal Drugs Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Long-acting Retinal Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Retinal Drugs Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Retinal Drugs Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Long-acting Retinal Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Long-acting Retinal Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Long-acting Retinal Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Long-acting Retinal Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Long-acting Retinal Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Long-acting Retinal Drugs include Janssen Pharmaceuticals (Johnson & Johnson), Takeda, Teva Pharmaceutical, Novartis, Merck, Bayer, Alcon Inc., AbbVie Inc. and ThromboGenics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Long-acting Retinal Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Long-acting Retinal Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Long-acting Retinal Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Long-acting Retinal Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Long-acting Retinal Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Long-acting Retinal Drugs revenue, projected growth trends, production technology, application and end-user industry.

Long-acting Retinal Drugs Segment by Company

Janssen Pharmaceuticals (Johnson & Johnson)

Takeda

Teva Pharmaceutical

Novartis

Merck

Bayer

Alcon Inc.

AbbVie Inc.

ThromboGenics

Regeneron

Oxurion NV

OncoGene Pharmaceuticals

MeiraGTx Limited

F. Hoffmann-La Roche

Bausch Health Co. Inc.

Allergan

Alimera Sciences Inc.

Long-acting Retinal Drugs Segment by Type

Chemically Synthesized Drugs

Biologics

Natural/Nutritional Supplements

Long-acting Retinal Drugs Segment by Application

Hospital

Clinic

Other

Long-acting Retinal Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Retinal Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Retinal Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Retinal Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Long-acting Retinal Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Long-acting Retinal Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Long-acting Retinal Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Long-acting Retinal Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Chemically Synthesized Drugs Major Player Table 3. Biologics Major Player Table 4. Natural/Nutritional Supplements Major Player Table 5. Global Long-acting Retinal Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Clinic Major Player Table 8. Other Major Player Table 9. Long-acting Retinal Drugs Industry Trends Table 10. Long-acting Retinal Drugs Industry Drivers Table 11. Long-acting Retinal Drugs Industry Opportunities and Challenges Table 12. Long-acting Retinal Drugs Industry Restraints Table 13. Global Long-acting Retinal Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Long-acting Retinal Drugs Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Long-acting Retinal Drugs Market Share by Region (2021-2026) Table 16. Global Long-acting Retinal Drugs Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Long-acting Retinal Drugs Market Share by Region (2027-2032) Table 18. Global Long-acting Retinal Drugs Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Long-acting Retinal Drugs Revenue Market Share by Players (2021-2026) Table 20. Global Long-acting Retinal Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Long-acting Retinal Drugs Key Players Headquarters & Area Served Table 22. Global Long-acting Retinal Drugs Players, Product Type & Application Table 23. Global Long-acting Retinal Drugs Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Long-acting Retinal Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Long-acting Retinal Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Long-acting Retinal Drugs Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Long-acting Retinal Drugs Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Long-acting Retinal Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Long-acting Retinal Drugs Revenue Market Share by Type (2027-2032) Table 31. Global Long-acting Retinal Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Long-acting Retinal Drugs Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Long-acting Retinal Drugs Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Long-acting Retinal Drugs Revenue Market Share by Application (2021-2026) Table 35. Global Long-acting Retinal Drugs Revenue Market Share by Application (2027-2032) Table 36. Janssen Pharmaceuticals (Johnson & Johnson) Company Information Table 37. Janssen Pharmaceuticals (Johnson & Johnson) Business Overview Table 38. Janssen Pharmaceuticals (Johnson & Johnson) Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Janssen Pharmaceuticals (Johnson & Johnson) Long-acting Retinal Drugs Product Portfolio Table 40. Janssen Pharmaceuticals (Johnson & Johnson) Recent Development Table 41. Takeda Company Information Table 42. Takeda Business Overview Table 43. Takeda Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Takeda Long-acting Retinal Drugs Product Portfolio Table 45. Takeda Recent Development Table 46. Teva Pharmaceutical Company Information Table 47. Teva Pharmaceutical Business Overview Table 48. Teva Pharmaceutical Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Teva Pharmaceutical Long-acting Retinal Drugs Product Portfolio Table 50. Teva Pharmaceutical Recent Development Table 51. Novartis Company Information Table 52. Novartis Business Overview Table 53. Novartis Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Novartis Long-acting Retinal Drugs Product Portfolio Table 55. Novartis Recent Development Table 56. Merck Company Information Table 57. Merck Business Overview Table 58. Merck Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Merck Long-acting Retinal Drugs Product Portfolio Table 60. Merck Recent Development Table 61. Bayer Company Information Table 62. Bayer Business Overview Table 63. Bayer Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Bayer Long-acting Retinal Drugs Product Portfolio Table 65. Bayer Recent Development Table 66. Alcon Inc. Company Information Table 67. Alcon Inc. Business Overview Table 68. Alcon Inc. Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Alcon Inc. Long-acting Retinal Drugs Product Portfolio Table 70. Alcon Inc. Recent Development Table 71. AbbVie Inc. Company Information Table 72. AbbVie Inc. Business Overview Table 73. AbbVie Inc. Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. AbbVie Inc. Long-acting Retinal Drugs Product Portfolio Table 75. AbbVie Inc. Recent Development Table 76. ThromboGenics Company Information Table 77. ThromboGenics Business Overview Table 78. ThromboGenics Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. ThromboGenics Long-acting Retinal Drugs Product Portfolio Table 80. ThromboGenics Recent Development Table 81. Regeneron Company Information Table 82. Regeneron Business Overview Table 83. Regeneron Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Regeneron Long-acting Retinal Drugs Product Portfolio Table 85. Regeneron Recent Development Table 86. Oxurion NV Company Information Table 87. Oxurion NV Business Overview Table 88. Oxurion NV Long-acting Retinal Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Oxurion NV Long-acting Retinal Drugs Product Portfolio Table 90. Oxurion NV Recent Development Table 91. OncoGene Pharmaceuticals Company Information Table 92. OncoGene Pharmaceuticals Business Overview Table 93. OncoGene Pharmaceuticals Long-acting Retinal Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. OncoGene Pharmaceuticals Long-acting Retinal Drugs Product Portfolio Table 95. OncoGene Pharmaceuticals Recent Development Table 96. MeiraGTx Limited Company Information Table 97. MeiraGTx Limited Business Overview Table 98. MeiraGTx Limited Long-acting Retinal Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. MeiraGTx Limited Long-acting Retinal Drugs Product Portfolio Table 100. MeiraGTx Limited Recent Development Table 101. F. Hoffmann-La Roche Company Information Table 102. F. Hoffmann-La Roche Business Overview Table 103. F. Hoffmann-La Roche Long-acting Retinal Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. F. Hoffmann-La Roche Long-acting Retinal Drugs Product Portfolio Table 105. F. Hoffmann-La Roche Recent Development Table 106. Bausch Health Co. Inc. Company Information Table 107. Bausch Health Co. Inc. Business Overview Table 108. Bausch Health Co. Inc. Long-acting Retinal Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Bausch Health Co. Inc. Long-acting Retinal Drugs Product Portfolio Table 110. Bausch Health Co. Inc. Recent Development Table 111. Allergan Company Information Table 112. Allergan Business Overview Table 113. Allergan Long-acting Retinal Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Allergan Long-acting Retinal Drugs Product Portfolio Table 115. Allergan Recent Development Table 116. Alimera Sciences Inc. Company Information Table 117. Alimera Sciences Inc. Business Overview Table 118. Alimera Sciences Inc. Long-acting Retinal Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Alimera Sciences Inc. Long-acting Retinal Drugs Product Portfolio Table 120. Alimera Sciences Inc. Recent Development Table 121. North America Long-acting Retinal Drugs Revenue by Type (2021-2026) & (US$ Million) Table 122. North America Long-acting Retinal Drugs Revenue by Type (2027-2032) & (US$ Million) Table 123. North America Long-acting Retinal Drugs Revenue by Application (2021-2026) & (US$ Million) Table 124. North America Long-acting Retinal Drugs Revenue by Application (2027-2032) & (US$ Million) Table 125. North America Long-acting Retinal Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. North America Long-acting Retinal Drugs Revenue by Country (2021-2026) & (US$ Million) Table 127. North America Long-acting Retinal Drugs Revenue by Country (US$ Million) & (2027-2032) Table 128. Europe Long-acting Retinal Drugs Revenue by Type (2021-2026) & (US$ Million) Table 129. Europe Long-acting Retinal Drugs Revenue by Type (2027-2032) & (US$ Million) Table 130. Europe Long-acting Retinal Drugs Revenue by Application (2021-2026) & (US$ Million) Table 131. Europe Long-acting Retinal Drugs Revenue by Application (2027-2032) & (US$ Million) Table 132. Europe Long-acting Retinal Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Europe Long-acting Retinal Drugs Revenue by Country (2021-2026) & (US$ Million) Table 134. Europe Long-acting Retinal Drugs Revenue by Country (US$ Million) & (2027-2032) Table 135. China Long-acting Retinal Drugs Revenue by Type (2021-2026) & (US$ Million) Table 136. China Long-acting Retinal Drugs Revenue by Type (2027-2032) & (US$ Million) Table 137. China Long-acting Retinal Drugs Revenue by Application (2021-2026) & (US$ Million) Table 138. China Long-acting Retinal Drugs Revenue by Application (2027-2032) & (US$ Million) Table 139. Asia Long-acting Retinal Drugs Revenue by Type (2021-2026) & (US$ Million) Table 140. Asia Long-acting Retinal Drugs Revenue by Type (2027-2032) & (US$ Million) Table 141. Asia Long-acting Retinal Drugs Revenue by Application (2021-2026) & (US$ Million) Table 142. Asia Long-acting Retinal Drugs Revenue by Application (2027-2032) & (US$ Million) Table 143. Asia Long-acting Retinal Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 144. Asia Long-acting Retinal Drugs Revenue by Region (US$ Million) & (2021-2026) Table 145. Asia Long-acting Retinal Drugs Revenue by Region (US$ Million) & (2027-2032) Table 146. SAMEA Long-acting Retinal Drugs Revenue by Type (2021-2026) & (US$ Million) Table 147. SAMEA Long-acting Retinal Drugs Revenue by Type (2027-2032) & (US$ Million) Table 148. SAMEA Long-acting Retinal Drugs Revenue by Application (2021-2026) & (US$ Million) Table 149. SAMEA Long-acting Retinal Drugs Revenue by Application (2027-2032) & (US$ Million) Table 150. SAMEA Long-acting Retinal Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 151. SAMEA Long-acting Retinal Drugs Revenue by Country (2021-2026) & (US$ Million) Table 152. SAMEA Long-acting Retinal Drugs Revenue by Country (US$ Million) & (2027-2032) Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources Table 156. Primary Sources List of Figures Figure 1. Long-acting Retinal Drugs Image Figure 2. Global Long-acting Retinal Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Retinal Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Chemically Synthesized Drugs Image Figure 5. Biologics Image Figure 6. Natural/Nutritional Supplements Image Figure 7. Global Long-acting Retinal Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Long-acting Retinal Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Clinic Image Figure 11. Other Image Figure 12. Global Long-acting Retinal Drugs Market Size (US$ Million) & (2021-2032) Figure 13. Global Long-acting Retinal Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Long-acting Retinal Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Long-acting Retinal Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Long-acting Retinal Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Long-acting Retinal Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Long-acting Retinal Drugs Revenue Market Share by Type (2021-2032) Figure 20. Global Long-acting Retinal Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Long-acting Retinal Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Long-acting Retinal Drugs Revenue Market Share by Application (2021-2032) Figure 23. North America Long-acting Retinal Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Long-acting Retinal Drugs Revenue Share by Type (2021-2032) Figure 25. North America Long-acting Retinal Drugs Revenue Share by Application (2021-2032) Figure 26. North America Long-acting Retinal Drugs Revenue Share by Country (2021-2032) Figure 27. United States Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Long-acting Retinal Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Long-acting Retinal Drugs Revenue Share by Type (2021-2032) Figure 32. Europe Long-acting Retinal Drugs Revenue Share by Application (2021-2032) Figure 33. Europe Long-acting Retinal Drugs Revenue Share by Country (2021-2032) Figure 34. Germany Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Long-acting Retinal Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Long-acting Retinal Drugs Revenue Share by Type (2021-2032) Figure 44. China Long-acting Retinal Drugs Revenue Share by Application (2021-2032) Figure 45. Asia Long-acting Retinal Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Long-acting Retinal Drugs Revenue Share by Type (2021-2032) Figure 47. Asia Long-acting Retinal Drugs Revenue Share by Application (2021-2032) Figure 48. Asia Long-acting Retinal Drugs Revenue Share by Region (2021-2032) Figure 49. Japan Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Long-acting Retinal Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Long-acting Retinal Drugs Revenue Share by Type (2021-2032) Figure 57. SAMEA Long-acting Retinal Drugs Revenue Share by Application (2021-2032) Figure 58. SAMEA Long-acting Retinal Drugs Revenue Share by Country (2021-2032) Figure 59. Brazil Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Long-acting Retinal Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Chemically Synthesized Drugs
  • Biologics
  • Natural/Nutritional Supplements
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Janssen Pharmaceuticals (Johnson & Johnson)
  • Takeda
  • Teva Pharmaceutical
  • Novartis
  • Merck
  • Bayer
  • Alcon Inc.
  • AbbVie Inc.
  • ThromboGenics
  • Regeneron
  • Oxurion NV
  • OncoGene Pharmaceuticals
  • MeiraGTx Limited
  • F. Hoffmann-La Roche
  • Bausch Health Co. Inc.
  • Allergan
  • Alimera Sciences Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Long-acting Retinal Drugs Market by Type
  3. 1.2.1 Global Long-acting Retinal Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Chemically Synthesized Drugs
  5. 1.2.3 Biologics
  6. 1.2.4 Natural/Nutritional Supplements
  7. 1.3 Long-acting Retinal Drugs Market by Application
  8. 1.3.1 Global Long-acting Retinal Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Clinic
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Long-acting Retinal Drugs Market Dynamics
  1. 2.1 Long-acting Retinal Drugs Industry Trends
  2. 2.2 Long-acting Retinal Drugs Industry Drivers
  3. 2.3 Long-acting Retinal Drugs Industry Opportunities and Challenges
  4. 2.4 Long-acting Retinal Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Long-acting Retinal Drugs Market Perspective (2021-2032)
  2. 3.2 Global Long-acting Retinal Drugs Growth Trends by Region
  3. 3.2.1 Global Long-acting Retinal Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Long-acting Retinal Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Long-acting Retinal Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Long-acting Retinal Drugs Revenue by Players
  2. 4.1.1 Global Long-acting Retinal Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Long-acting Retinal Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Long-acting Retinal Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Long-acting Retinal Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Long-acting Retinal Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Long-acting Retinal Drugs Players, Product Type & Application
  8. 4.5 Global Long-acting Retinal Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Long-acting Retinal Drugs Market CR5 and HHI
  11. 4.6.3 2025 Long-acting Retinal Drugs Tier 1, Tier 2, and Tier 3
5 Long-acting Retinal Drugs Market Size by Type
  1. 5.1 Global Long-acting Retinal Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Long-acting Retinal Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Long-acting Retinal Drugs Revenue Market Share by Type (2021-2032)
6 Long-acting Retinal Drugs Market Size by Application
  1. 6.1 Global Long-acting Retinal Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Long-acting Retinal Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Long-acting Retinal Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Janssen Pharmaceuticals (Johnson & Johnson)
  2. 7.1.1 Janssen Pharmaceuticals (Johnson & Johnson) Company Information
  3. 7.1.2 Janssen Pharmaceuticals (Johnson & Johnson) Business Overview
  4. 7.1.3 Janssen Pharmaceuticals (Johnson & Johnson) Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Janssen Pharmaceuticals (Johnson & Johnson) Long-acting Retinal Drugs Product Portfolio
  6. 7.1.5 Janssen Pharmaceuticals (Johnson & Johnson) Recent Developments
  7. 7.2 Takeda
  8. 7.2.1 Takeda Company Information
  9. 7.2.2 Takeda Business Overview
  10. 7.2.3 Takeda Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Takeda Long-acting Retinal Drugs Product Portfolio
  12. 7.2.5 Takeda Recent Developments
  13. 7.3 Teva Pharmaceutical
  14. 7.3.1 Teva Pharmaceutical Company Information
  15. 7.3.2 Teva Pharmaceutical Business Overview
  16. 7.3.3 Teva Pharmaceutical Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Teva Pharmaceutical Long-acting Retinal Drugs Product Portfolio
  18. 7.3.5 Teva Pharmaceutical Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Long-acting Retinal Drugs Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Merck
  26. 7.5.1 Merck Company Information
  27. 7.5.2 Merck Business Overview
  28. 7.5.3 Merck Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Merck Long-acting Retinal Drugs Product Portfolio
  30. 7.5.5 Merck Recent Developments
  31. 7.6 Bayer
  32. 7.6.1 Bayer Company Information
  33. 7.6.2 Bayer Business Overview
  34. 7.6.3 Bayer Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Bayer Long-acting Retinal Drugs Product Portfolio
  36. 7.6.5 Bayer Recent Developments
  37. 7.7 Alcon Inc.
  38. 7.7.1 Alcon Inc. Company Information
  39. 7.7.2 Alcon Inc. Business Overview
  40. 7.7.3 Alcon Inc. Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Alcon Inc. Long-acting Retinal Drugs Product Portfolio
  42. 7.7.5 Alcon Inc. Recent Developments
  43. 7.8 AbbVie Inc.
  44. 7.8.1 AbbVie Inc. Company Information
  45. 7.8.2 AbbVie Inc. Business Overview
  46. 7.8.3 AbbVie Inc. Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 AbbVie Inc. Long-acting Retinal Drugs Product Portfolio
  48. 7.8.5 AbbVie Inc. Recent Developments
  49. 7.9 ThromboGenics
  50. 7.9.1 ThromboGenics Company Information
  51. 7.9.2 ThromboGenics Business Overview
  52. 7.9.3 ThromboGenics Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 ThromboGenics Long-acting Retinal Drugs Product Portfolio
  54. 7.9.5 ThromboGenics Recent Developments
  55. 7.10 Regeneron
  56. 7.10.1 Regeneron Company Information
  57. 7.10.2 Regeneron Business Overview
  58. 7.10.3 Regeneron Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Regeneron Long-acting Retinal Drugs Product Portfolio
  60. 7.10.5 Regeneron Recent Developments
  61. 7.11 Oxurion NV
  62. 7.11.1 Oxurion NV Company Information
  63. 7.11.2 Oxurion NV Business Overview
  64. 7.11.3 Oxurion NV Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Oxurion NV Long-acting Retinal Drugs Product Portfolio
  66. 7.11.5 Oxurion NV Recent Developments
  67. 7.12 OncoGene Pharmaceuticals
  68. 7.12.1 OncoGene Pharmaceuticals Company Information
  69. 7.12.2 OncoGene Pharmaceuticals Business Overview
  70. 7.12.3 OncoGene Pharmaceuticals Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 OncoGene Pharmaceuticals Long-acting Retinal Drugs Product Portfolio
  72. 7.12.5 OncoGene Pharmaceuticals Recent Developments
  73. 7.13 MeiraGTx Limited
  74. 7.13.1 MeiraGTx Limited Company Information
  75. 7.13.2 MeiraGTx Limited Business Overview
  76. 7.13.3 MeiraGTx Limited Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 MeiraGTx Limited Long-acting Retinal Drugs Product Portfolio
  78. 7.13.5 MeiraGTx Limited Recent Developments
  79. 7.14 F. Hoffmann-La Roche
  80. 7.14.1 F. Hoffmann-La Roche Company Information
  81. 7.14.2 F. Hoffmann-La Roche Business Overview
  82. 7.14.3 F. Hoffmann-La Roche Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 F. Hoffmann-La Roche Long-acting Retinal Drugs Product Portfolio
  84. 7.14.5 F. Hoffmann-La Roche Recent Developments
  85. 7.15 Bausch Health Co. Inc.
  86. 7.15.1 Bausch Health Co. Inc. Company Information
  87. 7.15.2 Bausch Health Co. Inc. Business Overview
  88. 7.15.3 Bausch Health Co. Inc. Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Bausch Health Co. Inc. Long-acting Retinal Drugs Product Portfolio
  90. 7.15.5 Bausch Health Co. Inc. Recent Developments
  91. 7.16 Allergan
  92. 7.16.1 Allergan Company Information
  93. 7.16.2 Allergan Business Overview
  94. 7.16.3 Allergan Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Allergan Long-acting Retinal Drugs Product Portfolio
  96. 7.16.5 Allergan Recent Developments
  97. 7.17 Alimera Sciences Inc.
  98. 7.17.1 Alimera Sciences Inc. Company Information
  99. 7.17.2 Alimera Sciences Inc. Business Overview
  100. 7.17.3 Alimera Sciences Inc. Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Alimera Sciences Inc. Long-acting Retinal Drugs Product Portfolio
  102. 7.17.5 Alimera Sciences Inc. Recent Developments
8 North America
  1. 8.1 North America Long-acting Retinal Drugs Revenue (2021-2032)
  2. 8.2 North America Long-acting Retinal Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Long-acting Retinal Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Long-acting Retinal Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Long-acting Retinal Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Long-acting Retinal Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Long-acting Retinal Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Long-acting Retinal Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Long-acting Retinal Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Long-acting Retinal Drugs Revenue by Country
  11. 8.6.1 North America Long-acting Retinal Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Long-acting Retinal Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Long-acting Retinal Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Long-acting Retinal Drugs Revenue (2021-2032)
  2. 9.2 Europe Long-acting Retinal Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Long-acting Retinal Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Long-acting Retinal Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Long-acting Retinal Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Long-acting Retinal Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Long-acting Retinal Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Long-acting Retinal Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Long-acting Retinal Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Long-acting Retinal Drugs Revenue by Country
  11. 9.6.1 Europe Long-acting Retinal Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Long-acting Retinal Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Long-acting Retinal Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Long-acting Retinal Drugs Revenue (2021-2032)
  2. 10.2 China Long-acting Retinal Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Long-acting Retinal Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Long-acting Retinal Drugs Revenue by Type (2027-2032)
  5. 10.3 China Long-acting Retinal Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Long-acting Retinal Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Long-acting Retinal Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Long-acting Retinal Drugs Revenue by Application (2027-2032)
  9. 10.5 China Long-acting Retinal Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Long-acting Retinal Drugs Revenue (2021-2032)
  2. 11.2 Asia Long-acting Retinal Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Long-acting Retinal Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Long-acting Retinal Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Long-acting Retinal Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Long-acting Retinal Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Long-acting Retinal Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Long-acting Retinal Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Long-acting Retinal Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Long-acting Retinal Drugs Revenue by Country
  11. 11.6.1 Asia Long-acting Retinal Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Long-acting Retinal Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Long-acting Retinal Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Long-acting Retinal Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Long-acting Retinal Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Long-acting Retinal Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Long-acting Retinal Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Long-acting Retinal Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Long-acting Retinal Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Long-acting Retinal Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Long-acting Retinal Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Long-acting Retinal Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Long-acting Retinal Drugs Revenue by Country
  11. 12.6.1 SAMEA Long-acting Retinal Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Long-acting Retinal Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Long-acting Retinal Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst